{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:54:20Z","timestamp":1792043660225,"version":"4.4.0"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejmech.2025.118106","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T02:28:05Z","timestamp":1756434485000},"page":"118106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Recent update on the development of EZH2 inhibitors and degraders for cancer therapy"],"prefix":"10.1016","volume":"299","author":[{"given":"Meiyue","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoliang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118106_bib1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","article-title":"Cancer epigenetics: from mechanism to therapy","volume":"150","author":"Dawson","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.118106_bib2","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/nrm1761","article-title":"The diverse functions of histone lysine methylation","volume":"6","author":"Martin","year":"2005","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118106_bib3","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/WCO.0000000000000667","article-title":"The role of somatic mutational events in the pathogenesis of epilepsy","volume":"32","author":"Iffland","year":"2019","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.ejmech.2025.118106_bib4","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature09784","article-title":"The polycomb complex PRC2 and its mark in life","volume":"469","author":"Margueron","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118106_bib5","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1084\/jem.20181276","article-title":"Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML","volume":"216","author":"Basheer","year":"2019","journal-title":"The Journal of experimental medicine"},{"key":"10.1016\/j.ejmech.2025.118106_bib6","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature11606","article-title":"EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations","volume":"492","author":"McCabe","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118106_bib7","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.2005.01.5180","article-title":"EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast","volume":"24","author":"Bachmann","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118106_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13045-017-0547-3","article-title":"The polycomb group protein EZH2 induces epithelial-mesenchymal transition and pluripotent phenotype of gastric cancer cells by binding to PTEN promoter","volume":"11","author":"Gan","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118106_bib9","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1158\/1535-7163.MCT-17-0437","article-title":"Histone methyltransferase EZH2: a therapeutic target for ovarian cancer","volume":"17","author":"Jones","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejmech.2025.118106_bib10","doi-asserted-by":"crossref","first-page":"347ec110","DOI":"10.1126\/scitranslmed.aah3543","article-title":"EZH2 drives and defines an epigenetic subclass of lung cancer","volume":"8","author":"Beltran","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2025.118106_bib11","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nature01075","article-title":"The polycomb group protein EZH2 is involved in progression of prostate cancer","volume":"419","author":"Varambally","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118106_bib12","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm.4036","article-title":"Targeting EZH2 in cancer","volume":"22","author":"Kim","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2025.118106_bib13","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","article-title":"EZH2: a novel target for cancer treatment","volume":"13","author":"Duan","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118106_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100349","article-title":"Identification and characterization of second-generation EZH2 inhibitors with extended residence times and improved biological activity","volume":"296","author":"Stuckey","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib15","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1021\/acs.chemrev.6b00801","article-title":"Inhibitors of protein methyltransferases and demethylases","volume":"118","author":"Kaniskan","year":"2018","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2025.118106_bib16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41573-020-00108-x","article-title":"Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease","volume":"20","author":"Bhat","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118106_bib17","first-page":"156","article-title":"FDA approves an inhibitor of a novel 'epigenetic writer'","volume":"19","author":"Mullard","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118106_bib18","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s40265-022-01800-5","article-title":"Valemetostat tosilate: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118106_bib19","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1158\/0008-5472.CAN-24-0398","article-title":"Comprehensive target engagement by the EZH2 inhibitor tulmimetostat allows for targeting of ARID1A mutant cancers","volume":"84","author":"Keller","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118106_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11384","article-title":"Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance","volume":"7","author":"Brooun","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118106_bib21","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1182\/blood-2017-08-804344","article-title":"Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas","volume":"131","author":"Bisserier","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118106_bib22","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/s41388-018-0459-x","article-title":"miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer","volume":"38","author":"Sun","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.118106_bib23","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1158\/0008-5472.CAN-17-1327","article-title":"Tamoxifen resistance in breast cancer is regulated by the EZH2-ER\u03b1-GREB1 transcriptional axis","volume":"78","author":"Wu","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118106_bib24","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/s41556-022-00850-x","article-title":"EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis","volume":"24","author":"Wang","year":"2022","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118106_bib25","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1227604","article-title":"EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent","volume":"338","author":"Xu","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.118106_bib26","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1016\/j.celrep.2018.11.035","article-title":"Polycomb- and methylation-independent roles of EZH2 as a transcription activator","volume":"25","author":"Kim","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2025.118106_bib27","doi-asserted-by":"crossref","first-page":"10929","DOI":"10.1093\/nar\/gkac861","article-title":"A cryptic transactivation domain of EZH2 binds AR and AR's splice variant, promoting oncogene activation and tumorous transformation","volume":"50","author":"Wang","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2025.118106_bib28","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1038\/nm.3968","article-title":"SWI\/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2","volume":"21","author":"Kim","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2025.118106_bib29","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.ajpath.2021.01.013","article-title":"Noncanonical Functions of the Polycomb Group protein EZH2 in breast cancer","volume":"191","author":"Anwar","year":"2021","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejmech.2025.118106_bib30","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/s41388-023-02618-5","article-title":"Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader","volume":"42","author":"Yu","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.118106_bib31","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1038\/s41388-020-1332-2","article-title":"EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair","volume":"39","author":"Koyen","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.118106_bib32","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41568-021-00365-x","article-title":"Advancing targeted protein degradation for cancer therapy","volume":"21","author":"Dale","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2025.118106_bib33","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118106_bib34","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-Targeting chimeras as therapeutics and tools for biological discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.118106_bib35","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1039\/D3CS00100H","article-title":"Chemically induced degradation of epigenetic targets","volume":"52","author":"Kabir","year":"2023","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2025.118106_bib36","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41589-019-0421-4","article-title":"Discovery of a first-in-class EZH2 selective degrader","volume":"16","author":"Ma","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118106_bib37","doi-asserted-by":"crossref","first-page":"10167","DOI":"10.1021\/acs.jmedchem.1c00460","article-title":"Design, synthesis, and evaluation of VHL-Based EZH2 degraders to enhance therapeutic activity against lymphoma","volume":"64","author":"Tu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib38","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1021\/acsptsci.2c00100","article-title":"Targeting triple-negative breast cancer by a novel proteolysis targeting chimera degrader of enhancer of zeste homolog 2","volume":"5","author":"Dale","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ejmech.2025.118106_bib39","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1021\/acs.jmedchem.0c02234","article-title":"Design and synthesis of EZH2-Based PROTACs to degrade the PRC2 complex for targeting the noncatalytic activity of EZH2","volume":"64","author":"Liu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114462","article-title":"Discovery of precision targeting EZH2 degraders for triple-negative breast cancer","volume":"238","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.chembiol.2019.11.004","article-title":"EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 complex","volume":"27","author":"Hsu","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118106_bib42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.chembiol.2019.11.006","article-title":"Degradation of Polycomb repressive complex 2 with an EED-Targeted bivalent chemical degrader","volume":"27","author":"Potjewyd","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118106_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202205573","article-title":"Targeted degradation of PRC1 components, BMI1 and RING1B, via a novel protein complex degrader strategy","volume":"10","author":"Park","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ejmech.2025.118106_bib44","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/aps.2013.161","article-title":"EZH2: biology, disease, and structure-based drug discovery","volume":"35","author":"Tan","year":"2014","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2025.118106_bib45","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1076997","article-title":"Role of histone H3 lysine 27 methylation in Polycomb-group silencing","volume":"298","author":"Cao","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.118106_bib46","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0065-3233(04)67008-2","article-title":"Posttranslational modifications of histones by methylation","volume":"67","author":"Wood","year":"2004","journal-title":"Adv. Protein Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib47","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.biopha.2015.07.038","article-title":"Clinical and prognostic relevance of EZH2 in breast cancer: a meta-analysis","volume":"75","author":"Wang","year":"2015","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2025.118106_bib48","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4048\/jbc.2016.19.1.53","article-title":"High EZH2 protein expression is associated with poor overall survival in patients with luminal A breast cancer","volume":"19","author":"Jang","year":"2016","journal-title":"Journal of breast cancer"},{"key":"10.1016\/j.ejmech.2025.118106_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.126957","article-title":"Design and synthesis of (E)-1,2-diphenylethene-based EZH2 inhibitors","volume":"30","author":"He","year":"2020","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2025.118106_bib50","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/j.1349-7006.2011.01958.x","article-title":"Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker","volume":"102","author":"Takawa","year":"2011","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2025.118106_bib51","doi-asserted-by":"crossref","first-page":"7922","DOI":"10.1073\/pnas.1303800110","article-title":"Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2","volume":"110","author":"Knutson","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.ejmech.2025.118106_bib52","doi-asserted-by":"crossref","first-page":"9092","DOI":"10.1038\/s41598-018-27175-w","article-title":"An evolutionarily conserved structural platform for PRC2 inhibition by a class of Ezh2 inhibitors","volume":"8","author":"Bratkowski","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.118106_bib53","doi-asserted-by":"crossref","first-page":"25967","DOI":"10.1039\/C5RA02365C","article-title":"Design, synthesis and biological evaluation of novel 1-methyl-3-oxo-2, 3, 5, 6, 7, 8-hexahydroisoquinolins as potential EZH2 inhibitors","volume":"5","author":"Zhang","year":"2015","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2025.118106_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112617","article-title":"Covalent inhibitors of EZH2: design, synthesis and evaluation","volume":"147","author":"Zhang","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2025.118106_bib55","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd3410","article-title":"The resurgence of covalent drugs","volume":"10","author":"Singh","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118106_bib56","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nrd4103","article-title":"Irreversible kinase inhibitors gain traction","volume":"12","author":"Sanderson","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118106_bib57","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1039\/C7CS00220C","article-title":"Structure-based design of targeted covalent inhibitors","volume":"47","author":"Lonsdale","year":"2018","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2025.118106_bib58","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ejmech.2017.09.024","article-title":"Covalent binding design strategy: a prospective method for discovery of potent targeted anticancer agents","volume":"142","author":"Wang","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib59","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.15252\/embj.201694058","article-title":"A covalently bound inhibitor triggers EZH2 degradation through CHIP-mediated ubiquitination","volume":"36","author":"Wang","year":"2017","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2025.118106_bib60","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nchem.2479","article-title":"Counting on natural products for drug design","volume":"8","author":"Rodrigues","year":"2016","journal-title":"Nat. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib61","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1039\/D0CC04670A","article-title":"The discovery of SKLB-0335 as a paralog-selective EZH2 covalent inhibitor","volume":"57","author":"Zhang","year":"2021","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2025.118106_bib62","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1021\/acs.jmedchem.2c01370","article-title":"Discovery of a novel covalent EZH2 inhibitor based on tazemetostat scaffold for the treatment of ovarian cancer","volume":"66","author":"Zhang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib63","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1039\/D1CB00196E","article-title":"Lysine methyltransferase inhibitors: where we are now","volume":"3","author":"Feoli","year":"2022","journal-title":"RSC Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118106_bib64","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1158\/1535-7163.MCT-13-0773","article-title":"Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma","volume":"13","author":"Knutson","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejmech.2025.118106_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2023.129558","article-title":"Conformationally constrained potent inhibitors for enhancer of zeste homolog 2 (EZH2)","volume":"97","author":"Xu","year":"2024","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2025.118106_bib66","doi-asserted-by":"crossref","first-page":"15170","DOI":"10.1021\/acs.jmedchem.1c01154","article-title":"Discovery of IHMT-EZH2-115 as a potent and selective enhancer of zeste Homolog 2 (EZH2) inhibitor for the treatment of B-Cell lymphomas","volume":"64","author":"Zhou","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib67","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1021\/acsmedchemlett.0c00045","article-title":"Design, synthesis, and pharmacological evaluation of second generation EZH2 inhibitors with long residence time","volume":"11","author":"Khanna","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118106_bib68","doi-asserted-by":"crossref","first-page":"15586","DOI":"10.1021\/acs.jmedchem.4c01250","article-title":"Design, synthesis, and biological evaluation of potent EZH2\/LSD1 dual inhibitors for prostate cancer","volume":"67","author":"Le","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib69","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: challenges and opportunities in drug discovery","volume":"57","author":"Anighoro","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115461","article-title":"Recent advances in EZH2-based dual inhibitors in the treatment of cancers","volume":"256","author":"Yang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib71","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1158\/1535-7163.MCT-16-0471","article-title":"A novel LSD1 Inhibitor T-3775440 disrupts GFI1B-Containing complex leading to transdifferentiation and impaired growth of AML cells","volume":"16","author":"Ishikawa","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejmech.2025.118106_bib72","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1021\/acs.jmedchem.1c02156","article-title":"Structure-Activity relationship Study of Indolin-5-yl-cyclopropanamine derivatives as selective lysine specific demethylase 1 (LSD1) inhibitors","volume":"65","author":"Li","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib73","doi-asserted-by":"crossref","first-page":"6573","DOI":"10.1021\/acs.jmedchem.1c01876","article-title":"Design and synthesis of dual EZH2\/BRD4 inhibitors to target solid tumors","volume":"65","author":"Guo","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib74","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41467-017-02242-4","article-title":"Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors","volume":"9","author":"Kalin","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118106_bib75","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1021\/acs.jmedchem.2c01607","article-title":"Design, synthesis, and biological evaluation of a potent dual EZH2-BRD4 inhibitor for the treatment of some solid tumors","volume":"66","author":"Huang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib76","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.canlet.2017.10.015","article-title":"Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo","volume":"413","author":"Wen","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2025.118106_bib77","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.neo.2022.01.001","article-title":"UALCAN: an update to the integrated cancer data analysis platform","volume":"25","author":"Chandrashekar","year":"2022","journal-title":"Neoplasia"},{"key":"10.1016\/j.ejmech.2025.118106_bib78","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.neo.2017.05.002","article-title":"UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses","volume":"19","author":"Chandrashekar","year":"2017","journal-title":"Neoplasia"},{"key":"10.1016\/j.ejmech.2025.118106_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103808","article-title":"New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: design, synthesis and biological evaluation","volume":"99","author":"Liang","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib80","doi-asserted-by":"crossref","first-page":"14197","DOI":"10.1021\/acs.jmedchem.0c00919","article-title":"Tranylcypromine based Lysine-Specific Demethylase 1 inhibitor: summary and perspective","volume":"63","author":"Dai","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105335","article-title":"Targeting LSD1 for acute myeloid leukemia (AML) treatment","volume":"164","author":"Zhang","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2025.118106_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129726","article-title":"Design, synthesis and activity evaluation of quinolinone derivatives as EZH2 inhibitors","volume":"105","author":"Cai","year":"2024","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2025.118106_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117725","article-title":"Discovery of novel pyridone-benzamide derivatives possessing a 1-methyl-2-benzimidazolinone moiety as potent EZH2 inhibitors for the treatment of B-cell lymphomas","volume":"105","author":"Wu","year":"2024","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib84","doi-asserted-by":"crossref","first-page":"32646","DOI":"10.18632\/oncotarget.5066","article-title":"Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors","volume":"6","author":"Baker","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2025.118106_bib85","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/onc.2015.114","article-title":"Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors","volume":"35","author":"Gibaja","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.118106_bib86","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11899-018-0466-6","article-title":"Emerging EZH2 inhibitors and their application in lymphoma","volume":"13","author":"Lue","year":"2018","journal-title":"Current hematologic malignancy reports"},{"key":"10.1016\/j.ejmech.2025.118106_bib87","doi-asserted-by":"crossref","first-page":"12630","DOI":"10.1021\/acs.jmedchem.1c00567","article-title":"Discovery of first-in-class dual PARP and EZH2 inhibitors for triple-negative breast cancer with wild-type BRCA","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib88","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.molcel.2015.10.013","article-title":"PARP-1 activation requires local unfolding of an autoinhibitory domain","volume":"60","author":"Dawicki-McKenna","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2025.118106_bib89","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1021\/acs.jmedchem.8b00576","article-title":"Examination of Diazaspiro cores as piperazine bioisosteres in the Olaparib framework shows reduced DNA damage and cytotoxicity","volume":"61","author":"Reilly","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib90","doi-asserted-by":"crossref","first-page":"9575","DOI":"10.1021\/acs.jmedchem.6b00055","article-title":"An update on Poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors: opportunities and challenges in cancer therapy","volume":"59","author":"Wang","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib91","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1021\/acs.jmedchem.5b01501","article-title":"The importance of being me: magic methyls, methyltransferase inhibitors, and the discovery of tazemetostat","volume":"59","author":"Kuntz","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib92","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1021\/acs.jmedchem.7b01375","volume":"61","author":"Kung","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib93","doi-asserted-by":"crossref","first-page":"8194","DOI":"10.1021\/acs.jmedchem.0c02261","article-title":"Structure-Guided development of small-molecule PRC2 inhibitors targeting EZH2-EED interaction","volume":"64","author":"Du","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib94","doi-asserted-by":"crossref","first-page":"15344","DOI":"10.1021\/acs.jmedchem.0c01344","article-title":"Small molecule approaches for targeting the polycomb repressive complex 2 (PRC2) in cancer","volume":"63","author":"Martin","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib95","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/aps.2017.59","article-title":"Development of a high-throughput fluorescence polarization assay for the discovery of EZH2-EED interaction inhibitors","volume":"39","author":"Zhu","year":"2018","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2025.118106_bib96","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1248\/cpb.c19-00550","article-title":"Identification and assessments of novel and potent small-molecule inhibitors of EED-EZH2 interaction of Polycomb repressive complex 2 by computational methods and biological evaluations","volume":"68","author":"Zhu","year":"2020","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.ejmech.2025.118106_bib97","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.str.2007.08.007","article-title":"Structural basis of EZH2 recognition by EED","volume":"15","author":"Han","year":"2007","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2025.118106_bib98","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nchembio.1331","article-title":"Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer","volume":"9","author":"Kim","year":"2013","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118106_bib99","doi-asserted-by":"crossref","first-page":"9512","DOI":"10.1021\/jm501230c","article-title":"Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2","volume":"57","author":"Kong","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111715","article-title":"A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine","volume":"183","author":"Catalano","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib101","article-title":"Features of protein-protein interactions that translate into potent inhibitors: topology, surface area and affinity","volume":"14","author":"Smith","year":"2012","journal-title":"Expet Rev. Mol. Med."},{"key":"10.1016\/j.ejmech.2025.118106_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107419","article-title":"2,2- dimethylbenzopyran derivatives containing pyridone structural fragments as selective dual-targeting inhibitors of HIF-1\u03b1 and EZH2 for the treatment of lung cancer","volume":"147","author":"Xu","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib103","first-page":"2247","volume":"vol. 44","author":"Zhou","year":"2020"},{"key":"10.1016\/j.ejmech.2025.118106_bib104","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: an emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118106_bib105","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/487308a","article-title":"Chemical biology: greasy tags for protein removal","volume":"487","author":"Neklesa","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118106_bib106","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/nchembio.1658","article-title":"Pharmacological targeting of the pseudokinase Her3","volume":"10","author":"Xie","year":"2014","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118106_bib107","doi-asserted-by":"crossref","first-page":"7617","DOI":"10.1021\/acs.jmedchem.6b00855","article-title":"Structure-Activity relationship studies for enhancer of Zeste Homologue 2 (EZH2) and enhancer of Zeste Homologue 1 (EZH1) inhibitors","volume":"59","author":"Yang","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib108","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1021\/cb400133j","article-title":"An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1","volume":"8","author":"Konze","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118106_bib109","doi-asserted-by":"crossref","first-page":"9928","DOI":"10.1021\/acs.jmedchem.6b01315","volume":"59","author":"Vaswani","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib110","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11316","article-title":"Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2","volume":"7","author":"Justin","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118106_bib111","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejca.2016.12.019","article-title":"Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity","volume":"75","author":"Bate-Eya","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.118106_bib112","doi-asserted-by":"crossref","first-page":"8657","DOI":"10.1021\/jm5011258","article-title":"Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities","volume":"57","author":"Galdeano","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib113","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13312","article-title":"Potent and selective chemical probe of hypoxic signalling downstream of HIF-\u03b1 hydroxylation via VHL inhibition","volume":"7","author":"Frost","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118106_bib114","doi-asserted-by":"crossref","first-page":"E7285","DOI":"10.1073\/pnas.1803662115","article-title":"Delineating the role of cooperativity in the design of potent PROTACs for BTK","volume":"115","author":"Zorba","year":"2018","journal-title":"Proc. Natl. Acad. Sci. US.A."},{"key":"10.1016\/j.ejmech.2025.118106_bib115","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"Phthalimide conjugation as a strategy for in vivo target protein degradation","volume":"348","author":"Winter","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.118106_bib116","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41467-018-08027-7","article-title":"Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase","volume":"10","author":"Smith","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118106_bib117","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/anie.201507634","article-title":"Modular PROTAC design for the degradation of oncogenic BCR-ABL","volume":"55","author":"Lai","year":"2016","journal-title":"Angew. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib118","doi-asserted-by":"crossref","first-page":"7575","DOI":"10.1021\/acs.jmedchem.9b00871","article-title":"Potent and preferential degradation of CDK6 via proteolysis targeting chimera degraders","volume":"62","author":"Su","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib119","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1233606","article-title":"Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay","volume":"341","author":"Martinez Molina","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.118106_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113889","article-title":"Discovery of PT-65 as a highly potent and selective proteolysis-targeting chimera degrader of GSK3 for treating Alzheimer's disease","volume":"226","author":"Qu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106762","article-title":"Design, synthesis and evaluation of EZH2-based PROTACs targeting PRC2 complex in lymphoma","volume":"140","author":"Xie","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116154","article-title":"Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2","volume":"267","author":"Velez","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.107078","article-title":"Design, synthesis, and evaluation of VHL-based EZH2 degraders for breast cancer","volume":"143","author":"Xiao","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib124","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/aps.2017.7","article-title":"Structure of the PRC2 complex and application to drug discovery","volume":"38","author":"Shi","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2025.118106_bib125","doi-asserted-by":"crossref","first-page":"11774","DOI":"10.1021\/acs.jmedchem.1c00226","article-title":"Polycomb repressive complex 2 modulation through the development of EZH2-EED interaction inhibitors and EED binders","volume":"64","author":"Tomassi","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib126","doi-asserted-by":"crossref","first-page":"7016","DOI":"10.1021\/acs.jmedchem.2c00047","article-title":"Targeting enhancer of zeste homolog 2 for the treatment of hematological malignancies and solid tumors: candidate structure-activity relationships insights and evolution prospects","volume":"65","author":"Xia","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118106_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129968","article-title":"Chemically induced degradation of PRC2 complex by EZH2-Targeted PROTACs via a Ubiquitin-Proteasome pathway","volume":"113","author":"Fu","year":"2024","journal-title":"Bioorg. Med. Chem. Lett"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425008712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425008712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T17:41:28Z","timestamp":1757180488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425008712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":127,"alternative-id":["S0223523425008712"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118106","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent update on the development of EZH2 inhibitors and degraders for cancer therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118106","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118106"}}